

The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity



Markus G. Seidel, MD^{a,*}, Gerhard Kindle, MD, Dipl Inf^{b,c,*}, Benjamin Gathmann, MSc^b, Isabella Quinti, MD^d, Matthew Buckland, MD^e, Joris van Montfrans, MD, PhD^f, Raphael Scheible, MSc^b, Stephan Rusch^{b,c}, Lukas M. Gasteiger, Cm^a, Bodo Grimbacher, MD^{b,g,h,i}, Nizar Mahlaoui, MD, PhD^{j,†}, and Stephan Ehl, MD^{b,k,†}; on behalf of the ESID Registry Working Party and collaborators Graz, Austria; Freiburg, Germany; Rome, Italy; London, UK; Utrecht, the Netherlands; and Paris, France

Patient registries are instrumental for clinical research in rare diseases. They help to achieve a sufficient sample size for epidemiological and clinical research and to assess the feasibility of clinical trials. The European Society for Immunodeficiencies

(ESID) registry currently comprises information on more than 25,000 patients with inborn errors of immunity (IEI). The prerequisite of a patient to be included into the ESID registry is an IEI either defined by a defect in a gene included in the disease classification of the international union of immunological societies, or verified by applying clinical criteria. Because a relevant number of patients, including those with common variable immunodeficiency (CVID), representing the largest group of patients in the registry, remain without a genetic diagnosis, consensus on classification of these patients is mandatory. Here, we present clinical criteria for a large number of IEI that were designed in expert panels with an external review. They were implemented for novel entries and verification of existing data sets from 2014, yielding a substantial refinement. For instance, 8% of adults and 27% of children with CVID (176 of 1704 patients) were reclassified to 22 different immunodeficiencies, illustrating progress in genetics, but also the previous lack of standardized disease definitions. Importantly, apart from registry purposes, the clinical criteria are also helpful to support treatment decisions in the absence of a genetic diagnosis or in patients with variants of unknown significance. © 2019 American Academy of Allergy, Asthma & Immunology (J Allergy Clin Immunol Pract 2019;7:1763-70)

Key words: Primary immunodeficiency (PID); Primary immune deficiency and immune dysregulation disorder (PIDD); Guideline; Diagnostic algorithm; Classification; Consensus; Registry; Epidemiology

The diagnostic evaluation for primary immunodeficiency and immune dysregulation disorders (PID or PIDD, used synonymously), currently referred to as inborn errors of immunity (IEI), is typically initiated on the manifestation of (1) an increased severity or frequency of infections or an infection with an opportunistic microorganism, (2) symptoms of immune dysregulation like (multiorgan or early-onset) autoimmunity or autoinflammation, and/or (3) clinical signs of immunodeficiency in a patient with syndromic features or malignancy. Other signs like a positive family history, failure to thrive, lymphopenia, hypogammaglobulinemia, or prolonged need of intravenous antibiotic treatment are among the well-recognized alarm bells prompting physicians to initiate further testing for IEI. International consensus papers on clinical diagnostic algorithms guide the diagnostic procedure, and an increasing number of these

^aDivision of Pediatric Hemato-Oncology, Department of Pediatrics and Adolescent Medicine, Research Unit for Pediatric Hematology and Immunology, Medical University Graz, Graz, Austria

^bInstitute for Immunodeficiency, Center for Chronic Immunodeficiency (CCI), Medical Center — University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

^cCentral Facility Biobanking, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany

^dDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy

^eGreat Ormond St Hospital for Children NHS Foundation Trust and UCL Institute of Molecular and Cellular Immunology, Institute of Child Health, London, UK

^fPediatric Immunology and Infectious Diseases, UMC Utrecht, Utrecht, the Netherlands

^gDZIF, German Center for Infection Research, Satellite Center Freiburg, Freiburg, Germany

^hCIBSS — Centre for Integrative Biological Signalling Studies, Albert-Ludwigs University, Freiburg, Germany

ⁱRESIST — Cluster of Excellence 2155 to Hanover Medical School, Satellite Center Freiburg, Freiburg, Germany

^jCEREDIH, French National Reference Centre for Primary Immunodeficiencies and Pediatric Immuno-Hematology and Rheumatology Unit, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France

^kCenter for Pediatrics and Adolescent Medicine, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany

Conflicts of interest: M.G.S. is in part funded by the Styrian Children's Cancer Aid (Steirische Kinderkrebshilfe) Foundation. S.E. acknowledges support by the Bundesministerium für Bildung und Forschung (BMBF) (01EO1303) and the Deutsche Forschungsgemeinschaft (DFG) (Eh145/9-1 EURO-CID). G.K., R.S., and S.R. acknowledge support by the BMBF (BMBF 01GM0896, 01GM1111B, 01GM1517C, and 01EO1303). B.G. is supported by the German Research Foundation (DFG) under Germany's Excellence Strategy (CIBSS — EXC-2189 — Project ID 390939984) and through the Cluster of Excellence RESIST (EXC 2155; Project ID A2). The rest of the authors declare that they have no relevant conflicts of interest.

Received for publication December 17, 2018; revised February 5, 2019; accepted for publication February 6, 2019.

Available online February 15, 2019.

Corresponding authors: Markus G. Seidel, MD, Medical University Graz, Auenbruggerplatz 38, 8036 Graz, Austria. E-mail: markus.seidel@medunigraz.at; Or Stephan Ehl, MD, Institute for Immunodeficiency and Children's Hospital, University Hospital Freiburg, Breisacher Straße 115, 79106 Freiburg, Germany. E-mail: stephan.ehl@uniklinik-freiburg.de.

*These authors contributed equally to this work.

†These authors jointly coordinated and supervised this work.

2213-2198

© 2019 American Academy of Allergy, Asthma & Immunology

<https://doi.org/10.1016/j.jaip.2019.02.004>

Abbreviations used

CID- Combined immunodeficiency
CVID- Common variable immunodeficiency
ESID- European Society for Immunodeficiencies
IEI- Inborn errors of immunity
IUIS- International Union of Immunological Societies
PID- Primary immunodeficiency disorder
PIDD- Primary immune dysregulation disorder
SCID- Severe combined immunodeficiency
VUS- Variants of unknown significance

sets of warning signs have been analyzed for sensitivity and specificity.¹⁻⁵

Current technologies and the delineation of the human genome have enabled next-generation sequencing diagnostics for IEI by targeted gene panels, whole exome, or genome analysis, which are becoming available in more and more countries and centers globally. Because of reduced costs as compared with historical genetic analyses and proven cost efficiency, these novel genetic analysis tools are applied at earlier time points during hypothesis-driven diagnostic workup.^{6,7} Furthermore, the inclusion of severe combined or even other profound immunodeficiencies to newborn screening programs is becoming standard in many countries around the world because these diseases fulfill the medical genetics criteria for newborn screening, and screening is cost efficient, thereby tremendously supporting early diagnosis, improving management, and increasing survival of patients with IEI.⁸⁻¹¹ Today, more than 340 monogenic IEI are known, and the number is increasing rapidly. The International Union of Immunological Societies (IUIS) has biennially published a classification of PIDs that classifies PIDs into 9 categories according to the underlying molecular defect.¹² In addition to this genetic tabular list of PID disorders with brief descriptions of main laboratory and clinical findings, recently, a phenotype-driven diagnostic consensus paper has been added to extend and improve the practical use of this classification.¹³ The latter has also been made available as free application for mobile devices, further increasing its practical usefulness.^{14,15}

Patient registries are instrumental for clinical research in rare diseases. A registry for a large, heterogeneous and phenotypically overlapping group of disorders such as IEI needs stringent criteria for disease classification to allow appropriate data entry. Ideally, the registration title (ie, categorization) of every entry would be specific, undisputable, and verified. In the European Society for Immunodeficiencies (ESID) registry, the registration title entry is the IEI diagnosis. The IEI diagnosis is considered definitive in cases in which a known monogenic pathological variant was identified that explains the phenotype, although functional testing of variants is not required for validation to date. However, despite the advances of genetic diagnostic technologies, a majority of patients still lack a definitive genetic diagnosis. Therefore, clinical criteria were established by a panel of expert groups to correctly classify the majority of IEI disorders for patient inclusion into the ESID registry by disease category even if a genetic cause is unknown.

The ESID online registry was founded in 2004 and fulfills the role of a central IEI patient registry in Europe and some countries from other continents. It is a platform for clinical trials and

other research projects. It also represents a growing network of centers, connecting experts, immunological societies, and other stakeholders. This important role of the registry underpins the relevance of a stringent and reliable data set quality, setting the ground for high-quality studies in our field. Examples of published and ongoing studies using the ESID registry data are the activated PI3-kinase delta syndrome study, the study on unclassified predominantly antibody deficiencies, the common variable immunodeficiency (CVID) burden study, or a study on patients with ataxia telangiectasia.^{16,17} Numerous further papers using or highlighting the ESID registry have been published; please refer to the ESID registry publications website for an overview.¹⁸

A substantial amount of ESID registry data can be accessed by the public at the ESID registry web page,¹⁹ whereas more specific and detailed data can be retrieved and analyzed only by ESID registry members of a documenting center on login. Thirdly, data usage by third parties may be requested by submitting a research project proposal to the ESID registry working party or may be negotiated and is subject to a contract between the ESID and the institution/party requiring access. Data from the United Kingdom Primary Immunodeficiency Network are imported on a weekly interval, so that the total amount of data computed by the reporting/analysis tool are updated weekly. Publicly available ESID registry reports include number of patients in the registry, distribution between children and adults for every country, ESID registry patient numbers and proportions per IEI main diagnosis category and per country, yielding a map of the minimal prevalence of IEI, and ESID registry data on hematopoietic stem cell transplantation and gene therapy.¹⁹ The “members only” section allows more specific analyses for the patients entered by the member’s documenting center and the total of patients in the registry: for example, to show and export a list of IEI categories, subcategories, specific IEI diagnoses, and gene defects, to retrieve information on the country and sex distribution as well as the rate of coverage (difference from the expected geographical prevalence).

When the ESID registry was created, no central disease classification manual was available. The registry was then entirely restructured for quality assurance and data utility purposes in 2014. During the data transfer process from the previous to the current version, an obligatory verification step of the main title of an existing or of a novel entry, that is, the IEI diagnosis, was implemented. Thus, on choosing a diagnosis, the online entry system automatically generates a query asking whether the defined clinical criteria for the chosen diagnosis are fulfilled. The data manual also proposes to consider a number of alternative classifications if the criteria are not completely fulfilled. The present catalog of phenotypical criteria was designed to enable correct disease classification for patients with IEI who lack a definite genetic diagnosis at the time of registry inclusion, and, similar to the IUIS documents described above, represents continually updated work in progress.

MATERIALS AND METHODS

For each of 92 clinical IEI entities to be verified or excluded in patients who lack a genetic diagnosis, a number of mandatory and suggestive clinical features were defined by international experts and collected between 2013 and 2018. Drafts of proposed criteria were elaborated by experts in the field and were subsequently peer reviewed by 1 or more external experts in the respective category of IEI before implementation. Contributors and reviewers of each entity are stated. A regular quality




FIGURE 1. Simplified algorithm of a patient entry or diagnosis verification process in the ESID registry. *ESID*, European Society for Immunodeficiencies; *IEI*, inborn errors of immunity.

check and update of these criteria at a biennial basis is being coordinated through the ESID registry working party chair. For the illustration of diagnosis transition after implementation of the diagnosis verification process, we analyzed the reclassification of entries of CVID ($n = 1704$) on (1) clinical criteria, or (2) results of genetic testing in children and adults by drawing a Sankey diagram (The Sankey Diagram Generator, Acquire Procurement Services, Brisbane, Queensland, Australia; <http://sankey-diagram-generator.acquireprocure.com/>).

RESULTS: CLINICAL DIAGNOSIS CRITERIA FOR IEI AND THEIR APPLICATION

The document titled “ESID Registry—Working Definitions for Clinical Diagnosis of PID/IEI” is available in the Online Repository of this article (see [Table E1](#) in this article’s Online Repository at www.jaci-inpractice.org) and, in a regularly updated version, on the ESID website.²⁰ Recently, each diagnosis of the compilation was supplemented with OMIM (Online Mendelian Inheritance in Man) numbers of corresponding, genetically defined, diagnosis entities if available, and the respective category (1-9) of IEI according to the IUIS classification. This catalog may be downloaded and used for individual verification of a suspected IEI diagnosis before inclusion into the ESID registry. Furthermore, on initiation of a novel entry with a certain registration title (ie, IEI diagnosis), a pop-up window showing the respective criteria opens and requires their

confirmation. [Figure 1](#) illustrates the simple steps of including a patient into the ESID registry and verifying her or his diagnosis.

To analyze the benefit and demonstrate the effect of the implementation of a mandatory verification process, we evaluated the records of CVID in children (<18 years of age) and in adults before and after application of the diagnostic criteria in 2014. The clinical diagnostic criteria of CVID and, for comparison, of unclassified antibody deficiency and combined immunodeficiency (CID) are shown in [Table I](#). Of 1704 patients with the original diagnosis of CVID who were present in the registry when the verification process was implemented, 176 (10.3%) were reclassified into different diagnoses: twenty-four were reclassified on the basis of a detected monogenic defect not listed under CVID (13.6%), and 152 (86.4%) because they did not fulfill the consensus clinical CVID criteria ([Figure 2](#), and [Table E2](#), available in this article’s Online Repository at www.jaci-inpractice.org). Vice versa, 62 patients with other humoral immunodeficiencies (ie, other hypogammaglobulinemia, isolated IgG subclass deficiency, agammaglobulinemia, or other humoral or unclassified immunodeficiency) were reclassified to CVID during the verification process ([Figure 2](#)). Those who changed from CVID to other diagnoses based on mere clinical criteria were redefined as unclassified antibody deficiency ($n = 90$; 51.1%), isolated IgG subclass deficiency ($n = 15$; 8.5%), unclassified immunodeficiency ($n = 10$; 5.7%), CID ($n = 10$; 5.7%), agammaglobulinemia ($n = 3$; 1.7%), or other, rare, immunodeficiencies ($n = 24$; 13.6%; [Figure 2](#); see also [Table E2](#)). Patients originally classified as CVID who were reclassified to another

TABLE I. Examples of the ESID Registry—working definitions for clinical diagnosis of PID for common variable immunodeficiency (CVID), unclassified (predominantly) antibody deficiencies, and combined immunodeficiency (CID)

Disease	Contributors	Clinical criteria for a probable diagnosis (=clinical diagnosis)
CVID	Vojtech Thon, Natalia Martinez, Maria Kanariou, Klaus Warnatz, Isabella Quinti, Helen Chapel	At least one of the following: • increased susceptibility to infection • autoimmune manifestations • granulomatous disease • unexplained polyclonal lymphoproliferation • affected family member with antibody deficiency AND marked decrease of IgG and marked decrease of IgA with or without low IgM levels (measured at least twice; <2SD of the normal levels for their age) AND at least one of the following: • poor antibody response to vaccines (and/or absent isohemagglutinins); ie, absence of protective levels despite vaccination where defined • low switched memory B cells (<70% of age-related normal value) AND secondary causes of hypogammaglobulinemia have been excluded (eg, infection, protein loss, medication, malignancy) AND diagnosis is established after the fourth year of life (but symptoms may be present before) AND no evidence of profound T-cell deficiency, defined as 2 of the following (y = years of life): • CD4 numbers/microliter: 2-6 y < 300, 6-12 y < 250, >12 y < 200 • % naïve of CD4: 2-6 y < 25%, 6-16 y < 20%, >16 y < 10% • T-cell proliferation absent
Unclassified antibody deficiency	Esther de Vries, Nizar Mahlaoui, David Edgar, Isabella Quinti, Helen Chapel	At least one of the following: • Recurrent or severe bacterial infections • Autoimmune phenomena (especially cytopenias) • Polyclonal lymphoproliferation • Affected family member AND at least one of the following: • marked decrease of at least one of total IgG, IgG1, IgG2, IgG3, IgA, or IgM levels • failure of IgG antibody response(s) to vaccines AND secondary causes of hypogammaglobulinemia have been excluded (eg, infection, protein loss, medication, malignancy) AND no clinical signs of T-cell–related disease AND does not fit any of the other working definitions (excluding “unclassified immunodeficiencies”)
CID	Stephan Ehl, Maria Kanariou, Alain Fischer	At least one of the following: • at least one severe infection (requiring hospitalization) • one manifestation of immune dysregulation (autoimmunity, IBD, severe eczema, lymphoproliferation, granuloma) • malignancy • affected family member AND 2 of 4 T-cell criteria fulfilled: • reduced CD3 or CD4 or CD8 T cells (using age-related reference values) • reduced naïve CD4 and/or CD8 T cells • elevated g/d T cells • reduced proliferation to mitogen or TCR stimulation AND HIV excluded AND exclusion of a clinical diagnosis associated with CID (eg, defined syndromic diseases, DKC, AT, CHH)

AT, Ataxia teleangiectasia; CHH, cartilage hair hypoplasia; DKC, dyskeratosis congenita; IBD, inflammatory bowel disease; SD, standard deviation; TCR, T-cell receptor.

diagnosis on detection of a known genetic mutation were, in total, 24 (13.6%), and comprised various combined immunodeficiencies (n = 13; 7.4%), agammaglobulinemia (n = 5; 2.8%), or various other genetic diagnoses (n = 6; 3.4%) (Figures 2 and 3, and Table E2). For a comparison of the changes in diagnosis between children and adults, we performed this analysis separately, showing

that a substantially larger proportion of children than of adults previously entered under CVID changed their diagnosis (27.3% vs 7.7%). Interestingly, the proportion of genetic versus clinical redefinition during the routine diagnosis verification process was double in adults (19 of 114 adult patients, 16.6% genetic redefinition) as compared with children (5 of 62 children, 8.1% genetic




FIGURE 2. The ESID registry entries under the diagnosis of common variable immunodeficiency (CVID) before (left, $n = 1704$) and after (right, $n = 1590$) obligatory application of the ESID clinical criteria OR entry of a genetically confirmed diagnosis (direction from left to right). Other humoral immunodeficiencies that were later classified as CVID are shown in yellow (total $n = 62$); entries with CVID that were confirmed as CVID ($n = 1528$) or reclassified under a different IEI category based on clinical criteria are marked in green ($n = 152$; 86.4% of reclassified patients from CVID) or, if based on genetic criteria, in purple ($n = 24$; 13.6%), and are grouped for clarity. The thickness of lines/bars corresponds to the relative patient number. More detailed data are shown in Table E2 (available in this article's Online Repository at www.jaci-inpractice.org). ESID, European Society for Immunodeficiencies; IEI, inborn errors of immunity.

redefinition). However, the final distribution of diagnostic entities after reclassification was similar between children and adults (Figure 3 and Table E2).

DISCUSSION

The present document describes the development and current version of the ESID Registry Working Definitions for Clinical Diagnosis of PID/IEI as of January 2019, and comprises the entire spectrum of primary immunodeficiencies covered by the ESID registry to date. As it uses clinical disease definitions rather than separate genetic defects, this list may appear shorter than those provided in the IUIS documents. The document was designed to enable correct classification of patients without the known genetic cause of their disease within the ESID registry both for novel patient inclusions and for a mandatory verification process of existing entries starting from 2014. Furthermore, these "Clinical Diagnosis Criteria" are useful in clinical practice when making a working diagnosis of IEI in a patient who either lacks a genetic diagnosis or has a variant of unknown significance.

To demonstrate the effect of the introduction of a mandatory verification process of a clinical diagnosis entered into the ESID database, we chose CVID as an example, because of its high frequency among entries in the ESID registry (to date, 4773 of 25,023 patients [19%]) and its large proportion of patients

lacking a defined genetic defect (4593 of 4773 [96%] were merely clinically defined). The reclassification of a substantial proportion of patients with CVID, namely 27.3% of children and adolescents, and 7.7% of adults formerly entered under CVID into 22 other diagnoses reflects that a much higher resolution of the main item, that is, the IEI diagnosis, was achieved by implementing this obligatory step (Figure 1, step 2). Previously, patient classification solely depended on the assessment and choice of the physician or documentarist who entered the patient. The biggest target group of patients who changed their diagnosis from CVID to another was those later listed under unclassified antibody deficiencies, probably due to the fact that the criteria of the latter entity practically represent a subset but not all of those needed for CVID (Table 1). The fact that more than 1 of 4 children originally entered under CVID were reclassified indicates that the diagnosis of CVID is still being used too often in children and is important insofar as the identification of other diagnoses such as CID might imply a completely different therapeutic concept, for example, stem cell transplantation or targeted treatment. These observations suggest the requirement of a consensus definition of CVID in childhood, for which the present criteria might be a valid backbone.

The fact that a large proportion of patients who were later classified as CID or as agammaglobulinemia instead of CVID is due to the identification of a genetic cause is no surprise.




FIGURE 3. The subgroup of patients previously entered under common variable immunodeficiency (CVID) who were reclassified ($n = 176$) is shown separately for adults (blue) and children (red), and represents the bottom 10.3% of the dark gray bar on the left panel of Figure 2. Reclassification from CVID on the left was undertaken by using clinical diagnostic criteria (green) or a genetic diagnosis (purple) on the right, distinguishing children (red) and adults (blue) of the total of 1704 patients with the diagnosis of CVID (1477 adults and 227 children, of whom 1363 and 165, respectively, were verified as CVID and are shown in Figure 2). The thickness of lines/bars corresponds to the relative patient number. More detailed data are shown in Table E2 (available in this article's Online Repository at www.jaci-inpractice.org).

However, it is interesting that a much larger proportion of adults than of children with CVID underwent successful genetic diagnostics and were reclassified. However, because the ESID registry did not record negative genetic testing for patients classified and registered before verification, it is not possible to distinguish whether this difference is due to a higher proportion of adult patients as compared with children with a clinical phenotype of CVID who underwent successful genetic testing, or whether a larger proportion of children had already undergone genetic testing before classification and had been classified as monogenic ICI other than CVID. Likely, this difference will disappear with increased application of next-generation sequencing panel, exome, or genome diagnostics in all age groups driven by the availability of targeted treatment approaches.

An increasing number of patients with clinical features of ICI undergo next-generation sequencing diagnostics, but detected variants do not always represent variants known to explain the respective disease phenotype. The latest catalog of genes known to be potentially mutated in ICI and available for selection in the ESID registry for a patient entry, termed "ESID Online Registry—List of Diseases and Genes," can be downloaded from the ESID website.²¹ If a known genotype can be associated with multiple phenotypes and is thus listed under various disease entities, as, for instance, the case in a *RAG1* mutation, then the clinical diagnosis as defined by the documenting physician is required for the selection of the patient's registration title, that is,

the ICI diagnosis (eg, severe combined immunodeficiency [SCID], Omenn syndrome, atypical SCID, etc), but the application of clinical criteria is not needed. Until now, the ESID registry data section on genetic information does not collect information on variants of unknown significance (VUS), heterozygous variants that may be disease-causing, copy number variations, and it does not capture digenic or polygenic effects except for a free text entry possibility for "additional genes." Furthermore, with the only exception of *STAT3*, the differences between gain- or loss-of-function mutations, dominant negative effects, or haploinsufficiency are not distinguished. In the light of the challenges and needs arising from next-generation sequencing, a future version of the registry tab on genetic data should ideally collect information on the exact position of a mutation, the possibility of multiple gene defects, likely pathogenic variants, the functional effect of a detected mutation (if known or tested, and how), VUS, and combine them with more refined phenotypic details. Undoubtedly, these additions will require a substantial amount of programming work and resources, increasing the cost of information technology and maintenance on one hand, and more time per patient and dedication to accuracy of the documentarist, bearing the risk of a decrease in data completeness, quality, and stringency on the other hand.

In addition, in a subgroup of patients in whom a known genetic underpinning of ICI is identified, the phenotype differs

from the expected, genotype-associated, clinical picture. Some of these patients might have dual or multiple genotypes, leading to a mixed phenotype. In another subgroup of patients, the disease course might be progressive, leading to a shift from one, for example, CVID to CID or another IEI category. Today, unfortunately, such genotypical or phenotypical variations that represent potentially valuable additions to previous knowledge are not recorded within the ESID registry. If a patient's phenotype changes from one IEI diagnosis to another, and the gene defect is also listed under the new category, he or she can be reclassified to the new diagnosis. This new PID diagnosis and the complete history of previous documented diagnoses are recorded and shown in the user interface. Further shortcomings are, for example, that the system does not supervise the registration of patients with mutations that are not disease-causing, which is left to the interpretation of the documenting person, and the current system fails to account for patients who present with atypical phenotypes, if no disease-causing mutation has been identified. For now, the prime requisite for inclusion of a new patient into the ESID registry is the correct definition of an IEI diagnosis and its confirmation by the documentarist or physician. Currently, this step is not monitored or curated on a general basis. However, in specific subprojects (see level 2 and level 3, below), data monitoring is the responsibility of the respective study project committee and might be carried out for quality assurance on a study-specific basis. In its current form, the first level of an entry in the ESID registry with a defined IEI registration title (eg, "CVID") does not collect a vast number of additional patient- and disease-specific items other than type of presenting symptom (eg, infection, immune dysregulation, syndromic features, malignancy), diagnostic delay, way to and method of diagnosis, and main treatment modality (eg, immunoglobulin replacement, stem cell transplantation, gene therapy), because experience has shown a tendency that the quality of data sets decreases with their increasing size. However, optional additional levels of entries (level 2 and level 3 studies for subsets of patients) were created within the ESID registry for the purpose of answering hypothesis-driven study questions. The present Working Definitions for Clinical Diagnosis of PID/IEI provide the function of a standardized phenotypic diagnostic classification process and thereby enhance the discriminative depth and quality of individual data sets within the ESID registry without burdening participants with additional need to describe features that underlie the diagnosis after patient inclusion. In future, it may be conceivable to record the confirmatory steps of clinical criteria when they are applied during patient inclusion, for instance by recording "clicks" and translating this information into a standardized clinical code terminology, to accumulate even more individual disease-specific information. In line, the implementation of a yearly phenotype follow-up questionnaire, based on the same disease-specific clinical diagnostic criteria as at inclusion, might allow the collection of new important data on the natural disease courses, for example, in entities with progressive disease phenotypes, and to relate that to genetic data in future.

The usefulness and quality of data extracted from patient registries for rare diseases largely depend on correct data entry. It is thus of utmost importance for the ESID registry's quality assurance to review and check the disease classification of any newly added patient. With implementation of clinical criteria for 92 entities of IEI for patients who lack a monogenic underpinning of their disease, a substantial gain in refinement of the ESID

registry disease cohorts was achieved as demonstrated for CVID. Moreover, apart from their use for correct classification in the ESID database, we deem these criteria highly useful for making the correct diagnosis of IEI in the clinical setting. They may also be used to guide clinical and laboratory investigations, and support or dispute IEI working diagnoses that are not genetically confirmed. An extension of the use of these comprehensive, stringent, and consensus definitions of IEI for additional purposes such as clinical studies (eg, as inclusion or exclusion criteria), for establishing an IEI diagnosis, and for teaching purposes in clinical immunology is warranted. Together, the ESID registry clinical diagnostic criteria set a standard for making a diagnosis in IEI, either in patients without genetic diagnosis, as a starting point to make a genetic diagnosis, or in support of a definitive genetic diagnosis.

Acknowledgments

The authors would like to thank PPTA (<https://www.pptaglobal.org>) and its member companies for financial support of the ESID registry.

ESID Registry Working Party members and collaborators are as follows: Mario Abinun, Michael Albert, Sarah Beaussant Cohen, Jacinta Bustamante, Andrew Cant, Jean-Laurent Casanova, Helen Chapel, Genevieve de Saint Basile, Esther de Vries, Inderjeet Dokal, Jean Donadieu, Anne Durandy, David Edgar, Teresa Espanol, Amos Etzioni, Alain Fischer, Bobby Gaspar, Richard Gatti, Andrew Gennery, Sofia Grigoriadou, Steven Holland, Gritta Janka, Maria Kanariou, Christoph Klein, Helen Lachmann, Desa Lilic, Ania Manson, Natalia Martinez, Isabelle Meyts, Nicolette Moes, Despina Moshous, Benedicte Neven, Hans Ochs, Capucine Picard, Ellen Renner, Frederic Rieux-Laucat, Reinhard Seger, Annarosa Soresina, Dominique Stoppa-Lyonnet, Wojtech Thon, Adrian Thrasher, Frank van de Veer-donk, Anna Villa, Corry Weemaes, Klaus Warnatz, Beata Wol-ska, and Shen-Yin Zhang.

REFERENCES

- Modell V, Quinn J, Ginsberg G, Gladue R, Orange J, Modell F. Modeling strategy to identify patients with primary immunodeficiency utilizing risk management and outcome measurement. *Immunol Res* 2017;65:713-20.
- Lankisch P, Schiffner J, Ghosh S, Babor F, Borkhardt A, Laws HJ. The Duesseldorf warning signs for primary immunodeficiency: is it time to change the rules? *J Clin Immunol* 2015;35:273-9.
- Farmand S, Baumann U, von Bernuth H, Borte M, Foerster-Waldl E, Franke K, et al. Interdisciplinary AWMF guideline for the diagnostics of primary immunodeficiency [in German]. *Klin Padiatr* 2011;223:378-85.
- Arkwright PD, Gennery AR. Ten warning signs of primary immunodeficiency: a new paradigm is needed for the 21st century. *Ann N Y Acad Sci* 2011;1238:7-14.
- Costa-Carvalho BT, Grumach AS, Franco JL, Espinosa-Rosales FJ, Leiva LE, King A, et al. Attending to warning signs of primary immunodeficiency diseases across the range of clinical practice. *J Clin Immunol* 2014;34:10-22.
- Heimall JR, Hagin D, Hajjar J, Henrickson SE, Hernandez-Trujillo HS, Tan Y, et al. Use of genetic testing for primary immunodeficiency patients. *J Clin Immunol* 2018;38:320-9.
- Meyts I, Bosch B, Bolze A, Boisson B, Itan Y, Belkadi A, et al. Exome and genome sequencing for inborn errors of immunity. *J Allergy Clin Immunol* 2016;138:957-69.
- King JR, Hammarstrom L. Newborn screening for primary immunodeficiency diseases: history, current and future practice. *J Clin Immunol* 2018;38:56-66.
- Kwan A, Puck JM. History and current status of newborn screening for severe combined immunodeficiency. *Semin Perinatol* 2015;39:194-205.
- van der Spek J, Groenwold RH, van der Burg M, van Montfrans JM. TREC based newborn screening for severe combined immunodeficiency disease: a systematic review. *J Clin Immunol* 2015;35:416-30.

11. Modell V, Knaus M, Modell F. An analysis and decision tool to measure cost benefit of newborn screening for severe combined immunodeficiency (SCID) and related T-cell lymphopenia. *Immunol Res* 2014;60:145-52.
12. Picard C, Bobby Gaspar H, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. *J Clin Immunol* 2018;38:96-128.
13. Bousfiha A, Jeddane L, Picard C, Ailal F, Bobby Gaspar H, Al-Herz W, et al. The 2017 IUIS phenotypic classification for primary immunodeficiencies. *J Clin Immunol* 2018;38:129-43.
14. Horiyasoft. PID Phenotypical Diagnosis; 2017. Available from: <https://play.google.com/store/apps/details?id=com.horiyasoft.pidclassification>. Accessed January 25, 2019.
15. Ammouch A. PID Phenotypical Diagnosis; 2017. Available from: <https://itunes.apple.com/us/app/pid-phenotypical-diagnosis/id1160729399?mt=8>. Accessed January 25, 2019.
16. Maccari ME, Abolhassani H, Aghamohammadi A, Aiuti A, Aleinikova O, Bangs C, et al. Disease evolution and response to rapamycin in activated phosphoinositide 3-kinase delta syndrome: the European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase delta Syndrome Registry. *Front Immunol* 2018;9:543.
17. European Society for Immunodeficiencies. Registry Working Party Studies; 2018. Available from: <https://esid.org/Working-Parties/Registry-Working-Party/Studies>. Accessed January 25, 2019.
18. European Society for Immunodeficiencies. Registry Working Party Registry publications; 2018. Available from: <https://esid.org/Working-Parties/Registry-Working-Party/Registry-publications>. Accessed January 25, 2019.
19. European Society for Immunodeficiencies. Registry Working Party Reporting website; 2019. Available from: <https://esid.org/Working-Parties/Registry-Working-Party/Reporting-website>. Accessed January 25, 2019.
20. European Society for Immunodeficiencies. Registry Working Party Diagnosis criteria; 2018. Available from: <https://esid.org/Working-Parties/Registry-Working-Party/Diagnosis-criteria>. Accessed January 25, 2019.
21. European Society for Immunodeficiencies. Registry Working Party List of diseases and genes; 2019. Available from: <https://esid.org/Working-Parties/Registry-Working-Party/ESID-Registry/List-of-diseases-and-genes>. Accessed January 25, 2019.

Reproduced with permission of copyright owner. Further reproduction prohibited without permission.